Lataa...
Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases
Bevacizumab is FDA-approved in the treatment of primary brain tumors, but its efficacy in patients with brain metastases could be better-studied. This study examines a population of non-small cell lung cancer (NSCLC) patients with synchronous brain metastases to identify predictors of the decision t...
Tallennettuna:
| Julkaisussa: | Sci Rep |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group UK
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6882803/ https://ncbi.nlm.nih.gov/pubmed/31780762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-54513-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|